معرفی
Roles & Affiliations: David Thal is an Associate Professor (Research) in Drug Discovery Biology at Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. His work focuses on structural biology and drug discovery, particularly targeting G protein-coupled receptors (GPCRs) and ion channels like the P2X1 receptor. He leads projects addressing male contraception, Alzheimer’s disease, and heart failure through structural insights and cryo-electron microscopy (cryo-EM).
Research Interests: Thal’s research combines computational modeling, cryo-EM, and medicinal chemistry to design drugs targeting diseases such as neurocognitive disorders and cardiovascular conditions. Key areas include muscarinic receptor modulation, ligand-receptor interactions, and GPCR allostery. His lab explores novel therapies by mapping protein structures to identify allosteric binding sites and drug candidates.
Projects & Collaborations: Thal leads and participates in NHMRC-funded projects, including 'Using protein structure and dynamics to facilitate drug discovery' (2021–2025). He collaborates on developing P2X1 receptor antagonists for male contraception and alpha1-adrenoceptor tools for heart failure treatments. His work bridges structural biology with translational medicine, aiming to accelerate drug development.
Publications & Impact: Over 40 peer-reviewed articles highlight his contributions to cryo-EM methodologies, GPCR structure-function relationships, and drug design. Recent advances include high-resolution receptor structures and insights into ligand bias in muscarinic receptors. His work is published in top journals like Nature Communications, Science Advances, and Blood.
